Tumor detection and elimination by a targeted gallium corrole

Area of Science:

• Medicinal Chemistry
• Biotechnology
• Oncology

Background:

• Sulfonated gallium(III) corroles are fluorescent macrocycles capable of cell entry via protein assembly.
• Targeted drug delivery systems are crucial for improving cancer therapy efficacy and reducing systemic toxicity.

Purpose of the Study:

• To evaluate the in vivo imaging and therapeutic potential of a tumor-targeted corrole-protein complex.
• To compare the efficacy and safety of this novel complex against doxorubicin for cancer treatment.

Main Methods:

• A tumor-targeted corrole complex was created by noncovalently assembling a sulfonated gallium(III) corrole with a heregulin-modified protein targeting the human epidermal growth factor receptor (HER).
• In vivo imaging was performed to visualize tumor accumulation of the complex.
• Therapeutic efficacy was assessed by monitoring tumor cell death and tumor shrinkage.
• Safety was evaluated by examining effects on normal tissues, particularly cardiac tissue, and assessing immunogenicity.

Main Results:

• The protein-corrole complex accumulated in tumors, allowing for visualization through red corrole fluorescence.
• Targeted delivery resulted in significant tumor cell death and tumor ablation.
• The targeted complex demonstrated superior efficacy compared to doxorubicin, achieving greater tumor shrinkage at a lower dose.
• The corrole complex showed no damage to heart tissue and elicited no detectable immunogenicity.

Conclusions:

• The sulfonated gallium(III) corrole-protein complex serves as an effective agent for both tumor detection and therapeutic intervention.
• This targeted approach offers significant safety and efficacy advantages over standard chemotherapeutic agents like doxorubicin.
• The complex remains stable in serum, and the carrier protein is well-tolerated, indicating its potential for clinical translation.